Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.96 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.71 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9151137 | 0.98 | SIGMAR1 (1.00) | SIGMAR1TAAR1AOC3KCNH2 | |
| SCHEMBL10726207 | 0.98 | SIGMAR1 (1.00) | SIGMAR1TAAR1AOC3KCNH2 | |
| SCHEMBL9670745 | 0.98 | SIGMAR1 (1.00) | SIGMAR1TAAR1AOC3KCNH2 | |
| SCHEMBL5721858 | 0.98 | SIGMAR1 (1.00) | SIGMAR1TAAR1AOC3KCNH2 | |
| Hydrochloric Acid SCHEMBL5084990 | 0.98 | SIGMAR1 (0.92) | SIGMAR1TAAR1AOC3KCNH2 | |
| SCHEMBL8498144 | 0.98 | SIGMAR1 (1.00) | SIGMAR1TAAR1AOC3KCNH2 | |
| SCHEMBL2117266 | 0.98 | SIGMAR1 (1.00) | SIGMAR1TAAR1AOC3KCNH2 | |
| SCHEMBL8079373 | 0.98 | SIGMAR1 (1.00) | SIGMAR1TAAR1AOC3KCNH2 | |
| SCHEMBL22442307 | 0.98 | SIGMAR1 (1.00) | SIGMAR1TAAR1AOC3KCNH2 | |
| Iodide SCHEMBL5091516 | 0.98 | SIGMAR1 (0.92) | SIGMAR1TAAR1AOC3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008149053-A1 | BICYCL0 [2. 2. 1] HE PT- 2-YLAMINE DERIVATES AND THEIR USE | ARGENTA DISCOVERY LTD. (GB) | 2008-12-11 | — | — | WO | claimed |
| WO-2008096094-A1 | BICYCLOR[2.2.1]HEPT-7-YLAMINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR MODULATORS | ARGENTA DISCOVERY LTD. (GB) | 2008-08-14 | — | — | WO | claimed |
| EP-1924553-A1 | BICYCLO[2.2.]HEPT-7-YLAMINE DERIVATIVES AND THEIR USES | Argenta Discovery Limited (GB) | 2008-05-28 | — | — | EP | claimed |
| WO-2007017670-A1 | BICYCLO[2.2.]HEPT-7-YLAMINE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LTD. (GB) | 2007-02-15 | — | — | WO | claimed |
| EP-1187244-A2 | Organic amines as additives for electrochemical cells | MERCK PATENT GmbH (DE) | 2002-03-13 | — | — | EP | claimed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3728237-B1 | SUBSTITUTED THIOPHENYLURACILS , THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-02-09 | — | — | EP | disclosed |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| WO-2021026109-A1 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| US-10611786-B2 | Manganese (III) catalyzed C—H aminations | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190106448-A1 | MANGANESE (III) CATALYZED C--H AMINATIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-04-11 | — | — | US | disclosed |
| US-20190106448-A1 | MANGANESE (III) CATALYZED C--H AMINATIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-04-11 | — | — | US | disclosed |
| US-20030157407-A1 | Electrode material for rechargeable lithium battery, electrode structural body comprising said electrode material, rechargeable lithium battery having said electrode structural body, process for the production of said electrode structural body, and process for the production of said rechargeable lithium battery | CANON KABUSHIKI KAISHA (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1313158-A2 | Electrode material for rechargeable lithium battery, electrode comprising said electrode material, rechargeable lithium battery having said electrode , and process for the production thereof | CANON KABUSHIKI KAISHA (JP) | 2003-05-21 | — | — | EP | disclosed |
| EP-1187244-A2 | Organic amines as additives for electrochemical cells | MERCK PATENT GmbH (DE) | 2002-03-13 | — | — | EP | disclosed |
| US-5093370-A | Useful prior to insertion of tracheotomy tube or discission | TOBISHI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1992-03-03 | — | — | US | disclosed |
| US-4395410-A | Quaternary ammonium antiarrhythmic drugs | ELI LILLY AND COMPANY (US) | 1983-07-26 | — | — | US | disclosed |
| EP-0002604-B1 | QUATERNARY AMMONIUM SALTS, AND THEIR FORMULATIONS AND PREPARATION | ELI LILLY AND COMPANY (US) | 1983-05-04 | — | — | EP | disclosed |
| US-4289787-A | PROLONG ACTION POTENTIAL OF CARDIAC TISSUE | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| EP-0002604-A1 | Quaternary ammonium salts, and their formulations and preparation | ELI LILLY AND COMPANY (US) | 1979-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | SIGMAR1 3647/4885TAAR1 3175/4885AOC3 2447/4885 |
| US-10611786-B2 | Manganese (III) catalyzed C—H aminations | HLCS, NCL, NUDC | SIGMAR1 3247/4885TAAR1 3565/4885AOC3 59/4885 |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | SIGMAR1 2940/4885TAAR1 2823/4885AOC3 2579/4885 |
| US-20190106448-A1 | MANGANESE (III) CATALYZED C--H AMINATIONS | HLCS, NCL, NUDC | SIGMAR1 3307/4885TAAR1 3425/4885AOC3 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.